Table 1.
Clinical Characteristics
| Characteristics | Patients, no. (%) |
|---|---|
| Sex | |
| Male | 31 (70.5) |
| Female | 13 (29.5) |
| Age, years | |
| ≤ 70 | 26 (59.1) |
| > 70 | 18 (40.9) |
| AJCC Disease Stage | |
| IIIA | 21 (47.7) |
| IIIB | 23 (52.3) |
| Tumor Size and Node Status | |
| T1–2 | 22 (50) |
| T3–4 | 22 (50) |
| N0–1 | 10 (22.7) |
| N2–3 | 34 (77.3) |
| Tumor Histology | |
| Squamous | 25 (56.8) |
| Adenocarcinoma | 15 (34.1) |
| NSC NOS | 4 (9.1) |
| Gross Tumor Volume, cm3 | |
| Median (range) | 101.3 (4.1–753.2) |
| Karnofsky Performance Score | |
| Median (range) | 90 (70–100) |
| Status | |
| Alive | 22 (50) |
| Dead | 22 (50) |
| Follow-up time, days | |
| Median (range) | 592 (184–1333) |
| Chemotherapy | |
| Neoadjuvant chemotherapy | 11 (25) |
| Median no. cycles [range] | 3 [1–7] |
| Weekly chemotherapy | 44 (100) |
| Median no. cycles [range] | 7 [3–9] |
| Adjuvant chemotherapy | 8 (18.2) |
| Median no. cycles [range] | 2.5 [1–4] |
Abbreviations: AJCC, American Joint Committee on Cancer; NSC NOS, non-small-cell lung cancer, not otherwise specified.